Business
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results
INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $238 Million with Approximately 42,100 TRx INGREZZA® (valbenazine) Full-Year 2019 Net Product
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $238 Million with Approximately 42,100 TRx\n INGREZZA® (valbenazine) Full-Year 2019 Net Product Sales of $753 Million with Approximately 132,700 TRx\n\n\nSAN DIEGO, Feb. 4, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the fourth quarter and full-year ended December 31, 2019 and provided full-year 2020 financial expense guidance. \n\n \n \n\n \n\"I am very pleased with the accomplishments of Neurocrine Biosciences this past year, including our quarterly and full-year business results. We anticipate an exciting year ahead as we continue to build a leading global neuroscience-focused biopharmaceutical company,\" said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. \"In 2020, we will continue to focus on educating healthcare providers, caregivers and patients to help even more people suffering from the debilitating movements caused by tardive dyskinesia. In addition, we look forward to helping patients with Parkinson's disease with the anticipated approval of opicapone and the potential expanded use of elagolix to help women with uterine fibroids. By mid-2020, our activities position us to have three approved treatments in four indications and three additional ongoing pivotal studies.\"\nFourth Quarter and Full-Year 2019 Financial Highlights \nThree Months Ended\nDecember 31,\nYear Ended\nDecember 31,\n(unaudited, in millions, except per share data)\n2019\n2018\n2019\n2018\nRevenues:\nINGREZZA product sales, net\n$\n237.9\n$\n130.3\n$\n752.9\n$\n409.6\nCollaboration revenue\n6.2\n1.1\n35.2\n41.6\nTotal revenues\n$\n244.1\n$\n131.4\n$\n788.1\n$\n451.2\nGAAP R&D\n$\n55.3\n$\n34.5\n$\n200.0\n$\n155.8\nNon-GAAP R&D\n$\n47.9\n$\n29.9\n$\n164.2\n$\n119.6\nGAAP SG&A\n$\n101.3\n$\n69.0\n$\n354.1\n$\n248.9\nNon-GAAP SG&A\n$\n87.4\n$\n60.5\n$\n304.6\n$\n217.1\nGAAP net income\n$\n34.0\n$\n18.0\n$\n37.0\n$\n21.1\nGAAP net income per share – diluted\n$\n0.35\n$\n0.19\n$\n0.39\n$\n0.22\nNon-GAAP net income\n$\n102.2\n$\n38.4\n$\n283.8\n$\n70.5\nNon-GAAP net income per share – diluted\n$\n1.05\n$\n0.40\n$\n2.96\n$\n0.74\nDecember 31,\n(unaudited, in millions)\n2019\n2018\nCash, cash equivalents and marketable securities\n$\n970.2\n$\n866.9\nFourth Quarter and Full Year Net Product Sales Highlights:\nING...